Last Updated on June 16, 2021 by The Health Master
Zydus Cadila has received tentative approval from the USFDA to market Brivaracetam Tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg (US RLD: Briviact Tablets). Brivaracetam is used to treat partial-onset of seizures (epilepsy).
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Lupin gets warning letter from USFDA for Somerset facility
Lupin gets USFDA nod for generic drug to treat HIV infection
Glenmark gets USFDA nod for Theophylline ER tablets
Zydus Cadila gets tentative USFDA nod for Osimertinib Tablets
Zydus Cadila gets USFDA nod for Fluphenazine HCL Tablets
Glenmark gets USFDA nod for Icatibant injection single-dose prefilled syringe
Application Forms: Drugs, Cosmetics and Medical Devices
WHO asks China to cooperate with probe into origins of C-19
Probe ordered into black marketing of Remdesivir
Lupin gets warning letter from USFDA for Somerset facility
Supreme Court refuses to waive off final exams of PG courses
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon: